Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | USP2 | O75604 | 1/20 | 0.87 |
| ▸ | POLB | P06746 | 1/20 | 0.87 |
| ▸ | PPARG | P37231 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.87 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.49 |
| ▸ | APLNR | P35414 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838400 | 1.00 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29355331 | 0.93 | MEN1 (1.00) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL16593265 | 0.93 | MEN1 (1.00) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL1083748 | 0.92 | MEN1 (0.74) | MEN1USP2POLBPPARGBLM | |
| Water SCHEMBL7715721 | 0.92 | MEN1 (0.98) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29352150 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL18483 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL31011003 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL31011004 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL15384055 | 0.89 | MEN1 (0.69) | MEN1USP2POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059144-A1 | DYNAMIC NANOMECHANICAL AMPLIFICATION ANTENNA AND USES | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-03-20 | — | — | WO | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| US-20220237930-A1 | CELL AGE CLASSIFICATION AND DRUG SCREENING | FOUNTAIN THERAPEUTICS INC (US) | 2022-07-28 | — | — | US | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260140105-A1 | METHODS AND SYSTEMS FOR ANALYTE DETECTION AND ANALYSIS | ULTIMA GENOMICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139290-A1 | METHODS AND/OR USE OF OLIGONUCLEOTIDE CONJUGATES FOR ASSAYS AND FLOW CYTOMETRY DETECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12631645-B2 | Detection of BCL-2 family heterodimer complexes and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132459-A1 | COMPOSITIONS AND METHODS FOR PREPARING NUCLEIC ACID NANOSTRUCTURES USING COMPACTION OLIGONUCLEOTIDES | ELEMENT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260135108-A1 | POLYMER BINDER INCLUDING A TAG FOR USE IN ELECTROCHEMICAL CELLS | GM GLOBAL TECH OPERATIONS LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132442-A1 | SPATIALLY RESOLVED SURFACE CAPTURE OF NUCLEIC ACIDS | ELEMENT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739794-A1 | METHODS, COMPOSITONS, AND SYSTEMS FOR ANALYTE DETECTION | Stellaromics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20220042097-A1 | IN-SITU SPATIAL TRANSCRIPTOMICS AND PROTEOMICS | THE BROAD INSTITUTE, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220043249-A1 | PLANAR AREA LIGHT SOURCE | ESSENLIX CORPORATION (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220042110-A1 | DETECTION OF GENE FUSIONS BY INTRAGENIC DIFFERENTIAL EXPRESSION (IDE) USING AVERAGE CYCLE THRESHOLDS | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11242564-B2 | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-02-08 | — | — | US | disclosed |
| US-20220034869-A1 | MULTI-STAGE, MULTIPLEXED TARGET ISOLATION AND PROCESSING FROM HETEROGENEOUS POPULATIONS | THE BROAD INSTITUTE, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11237113-B2 | Rapid pH measurement | ESSENLIX CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| CN-108449995-B | Representative diagnosis | 文塔纳医疗系统公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2022020234-A2 | IMMUNOASSAY FOR SARS-COV-2 NEUTRALIZING ANTIBODIES AND MATERIALS THEREFOR | BIO-RAD LABORATORIES, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| US-11230736-B2 | Methods for assessing pregnancy outcome | INSERM (INSTITUT NATIONAL DE LA SANTÉ DE LA RECHERCHE MÉDICALE) (FR) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139290-A1 | METHODS AND/OR USE OF OLIGONUCLEOTIDE CONJUGATES FOR ASSAYS AND FLOW CYTOMETRY DETECTIONS | CD74, BCR, CD2BP2 | MEN1 4418/4885USP2 3346/4885POLB 344/4885 |
| US-12631645-B2 | Detection of BCL-2 family heterodimer complexes and use thereof | BCL2L10, BCL2L1, BCL2L2 | MEN1 2107/4885USP2 427/4885POLB 2879/4885 |
| US-20260140105-A1 | METHODS AND SYSTEMS FOR ANALYTE DETECTION AND ANALYSIS | SRMS, CFD, STUB1 | MEN1 1632/4885USP2 574/4885POLB 2444/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | MEN1 1825/4885USP2 1638/4885POLB 4367/4885 |
| US-20260132442-A1 | SPATIALLY RESOLVED SURFACE CAPTURE OF NUCLEIC ACIDS | POLM, RNGTT, CPSF6 | MEN1 4503/4885USP2 1468/4885POLB 29/4885 |
| US-20260132459-A1 | COMPOSITIONS AND METHODS FOR PREPARING NUCLEIC ACID NANOSTRUCTURES USING COMPACTION OLIGONUCLEOTIDES | PCNA, POLM, RNGTT | MEN1 4246/4885USP2 2231/4885POLB 15/4885 |
| US-20260135108-A1 | POLYMER BINDER INCLUDING A TAG FOR USE IN ELECTROCHEMICAL CELLS | VCL, VAPB, CHMP4B | MEN1 1576/4885USP2 4603/4885POLB 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.